Steric Hindrance of Antibody Binding to Surface Proteins of Coxiella Burnetti by Phase I Lipopolysaccharide
Overview
Authors
Affiliations
The exposure of surface protein antigens on virulent phase I Coxiella burnetti was compared with that on avirulent phase II cells. Although anti-phase II antibodies did not bind to the surfaces of native intact phase I cells, they bound to phase I proteins if the proteins were solubilized for sodium dodecyl sulfate-polyacrylamide gel electrophoresis and analyzed by immunoblotting. In addition, removal of the phase I lipopolysaccharide (LPS) by trichloroacetic acid exposed surface proteins for reactivity with anti-phase II antibodies, as shown by immunofluorescence assays, direct antibody binding, and immunoelectron microscopy using protein A-colloidal gold conjugates. Based on these observations, a simple model of phase variation is proposed to explain the apparently conflicting notions of the identity of the phase II antigen(s). The model suggests that the phase I LPS sterically hinders access of anti-phase II antibodies to a multitude of shared protein antigens, any one of which may confer phase II specificity. Exposure of these shared protein antigens through the appearance of a more truncated LPS (phase II) or extraction of the smooth-type phase I LPS allows antibody accessibility and therefore confers apparent phase II serospecificity.
Schaik E, Fratzke A, Gregory A, Dumaine J, Samuel J Front Cell Infect Microbiol. 2024; 14:1282183.
PMID: 38567021 PMC: 10985213. DOI: 10.3389/fcimb.2024.1282183.
Yanez U, Alvarez J, Pison C, Accion A, Becerra J, Jimenez A Animals (Basel). 2024; 14(3).
PMID: 38338010 PMC: 10854522. DOI: 10.3390/ani14030367.
Natural reversion promotes LPS elongation in an attenuated Coxiella burnetii strain.
Long C, Beare P, Cockrell D, Binette P, Tesfamariam M, Richards C Nat Commun. 2024; 15(1):697.
PMID: 38267444 PMC: 10808227. DOI: 10.1038/s41467-023-43972-y.
Q Fever: A troubling disease and a challenging diagnosis.
Miller H, Priestley R, Kersh G Clin Microbiol Newsl. 2023; 43(13):109-118.
PMID: 37701818 PMC: 10493821. DOI: 10.1016/j.clinmicnews.2021.06.003.
Multivalent vaccines demonstrate immunogenicity and protect against aerosol challenge.
Jan S, Fratzke A, Felgner J, Hernandez-Davies J, Liang L, Nakajima R Front Immunol. 2023; 14:1192821.
PMID: 37533862 PMC: 10390735. DOI: 10.3389/fimmu.2023.1192821.